Clinical research in pediatric patients is necessary to develop safe and effective medicines for children. US Food and Drug Administration (FDA) human subject protection regulations (21 Code of Federal Regulations 50, subpart D) require that, with limited exceptions, research in children that exceeds a defined level of risk must offer a prospect of direct benefit to the individual child that is sufficient to justify those risks. Growing attention to the merits of initiating pediatric clinical trials earlier in the drug and biological product development process has led the FDA to look more closely at the meaning of the regulatory term prospect of direct benefit. In collaboration with the FDA, the Duke-Margolis Center for Health Policy convened a workshop with leading experts in the fields of biomedical ethics, pediatric clinical research, and pediatric product development, as well as patient representatives, to discuss the FDA’s approach to characterizing prospect of direct benefit in the context of scientific advances in product development. Workshop topics included the extrapolation of adult efficacy data to children, use of nonclinical models of disease, use of modeling and simulation to support pediatric dosing, and reliance on biomarkers and surrogate end points in clinical research. Discussion from the workshop is provided herein to communicate the challenges that investigators, industry sponsors, regulators, and institutional review boards face when evaluating pediatric research and to outline several approaches to maximize prospect of direct benefit, minimize unnecessary risks and burden, and facilitate timely access to safe and effective medicines for children.
Prospect of Direct Benefit in Pediatric Trials: Practical Challenges and Potential Solutions
POTENTIAL CONFLICT OF INTEREST: Dr Joffe receives research funding from Pfizer through a grant to the University of Pennsylvania; the other authors have indicated they have no financial relationships relevant to this article to disclose.
FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.
- Views Icon Views
- Share Icon Share
- Search Site
Melanie Bhatnagar, Sarah Sheehan, Isha Sharma, Gerri Baer, Dionna Green, Susan McCune, Steven Joffe, Donna Snyder; Prospect of Direct Benefit in Pediatric Trials: Practical Challenges and Potential Solutions. Pediatrics May 2021; 147 (5): e2020049602. 10.1542/peds.2020-049602
Download citation file: